MIMS Education
Choosing a Long Acting Injectable (LAI) Anti-Psychotic: Patient & Prescriber Perspective on Treatment
Cat 3A: 1 Point | 
2h | 
22 Jun 2018
Overview
About this course
Multiple relapses characterize the course of disease in most patients with schizophrenia. Long-acting injectable (LAI) antipsychotics can help improve adherence to schizophrenia therapy to minimize relapse episodes. In a dinner symposium sponsored by Lundbeck, Professor Nagesh Pai of the University of Wollongong, Australia, discussed the benefits of LAI antipsychotics with focus on aripiprazole once-monthly (Abilify Maintena®) and reviewed clinical considerations for their use in schizophrenia.
1 CME Point Available (Category 3A)
- Complete the videos and quiz to qualify for 1 CME Point (Category 3A).
- A certificate will be provided upon successful completion. Please use the information on the certificate to claim your points via SMC website.
- Doctors who have attended the face-to-face meeting will not be eligible for additional CME points for completing this module.
Our Speaker
Professor Pai is currently a Professor & Academic Leader of Psychiatry at the University of Wollongong and Senior Clinical Academic, Psychogeriatric services at the Illawarra Shoalhaven Local Health District.
- Adjunct Professor of Psychiatry & Medical Education at Manipal University
- Visiting Professor of Psychiatry at SRM University in India
Find out more about Professor Pai in the module.
Organized by
An educational talk supported by Lundbeck
